Phase 2a, Multicenter, Masked, Randomized, Comparator Controlled Study Evaluating iSONEP™ as Monotherapy or Adjunctive Therapy to Lucentis/Avastin/Eylea Versus Lucentis/Avastin/Eylea Alone for Treatment of Subjects With Choroidal Neovascularization (CNV) Secondary to Age-related Macular Degeneration (AMD)

Trial Profile

Phase 2a, Multicenter, Masked, Randomized, Comparator Controlled Study Evaluating iSONEP™ as Monotherapy or Adjunctive Therapy to Lucentis/Avastin/Eylea Versus Lucentis/Avastin/Eylea Alone for Treatment of Subjects With Choroidal Neovascularization (CNV) Secondary to Age-related Macular Degeneration (AMD)

Completed
Phase of Trial: Phase II

Latest Information Update: 21 Oct 2016

At a glance

  • Drugs Sonepcizumab (Primary) ; Aflibercept; Bevacizumab; Ranibizumab
  • Indications Wet age-related macular degeneration
  • Focus Therapeutic Use
  • Acronyms Nexus
  • Sponsors Lpath
  • Most Recent Events

    • 15 Sep 2015 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.
    • 20 May 2015 Full results will be presented at the American Academy of Ophthalmology in November 2015, according to Lpath media release.
    • 20 May 2015 Results published in the Media Release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top